Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 202 UK small molecule drug companies below.
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery…
Oncology biotech developing peptide therapeutics and diagnostics
ValiRx is a UK-listed biopharmaceutical company focused on the development of oncology therapeutics and companion diagnostics. The company selects and incubates novel drug…
Chiral and achiral chromatography services for small molecule purification
Reach Separations is a contract chromatography company specialising in the analysis and purification of small molecules for clients in the pharmaceutical, agrochemical, and fine…
Precision medicine biotech targeting psychiatric and neurological conditions
Monument Therapeutics is a clinical-stage biotechnology company applying precision medicine to CNS drug development. The company uses proprietary digital biomarkers to stratify…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic…
Targeting developmentally-silent oncogenic drivers for cancer therapy
Awen Oncology is a Welsh oncology biotechnology company developing first-in-class therapeutics that target cancer-specific proteins derived from developmental genes that are…
Immunometabolism-targeting small molecules for autoimmune disease
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a…
Automated liquid handling and sample management instruments
SPT Labtech is a designer and manufacturer of laboratory automation instruments and consumables for liquid handling, sample preparation, and sample management. Its product…
NLRP3 inflammasome inhibitors for chronic inflammatory disease
NodThera is a clinical-stage biotechnology company developing potent and selective small molecule inhibitors of the NLRP3 inflammasome for diseases driven by chronic inflammation.…
Novel small-molecule anti-fibrinolytic for acute traumatic and surgical bleeding
ClotProtect Therapeutics is a University of Leeds spin-out developing a first-in-class small molecule anti-fibrinolytic to address acute bleeding following trauma and surgery. The…